Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TCR alpha/beta+/CD19+ depleted hematopoietic cells |
| Trade Name | |
| Synonyms | TCR alpha/beta+/CD19+ depleted HPCs||TCR alpha/beta/CD19-depleted HPCs |
| Drug Descriptions |
TCR alpha/beta+/CD19+ depleted hematopoietic cells is a preparation of donor hematopoietic progenitor cells that have been treated to remove the CD19 and TCRalpha/beta-expressing populations, potentially resulting in decreased graft vs. host disease after transplantation (PMID: 27811849, PMID: 29431621). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C157370 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| TCR alpha/beta+/CD19+ depleted hematopoietic cells | TCR alpha/beta+/CD19+ depleted hematopoietic cells | 0 | 1 |